Price
No data yet.
Social Signal Score
Revenue
$20.27M+5165.45%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Lisa A. Conte
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 47
- Beta
- -0.05
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -18.02
Financials
Revenue
$20.27M+5165.5%Net Income
$8.60MEBITDA
$9.94MFree Cash Flow
$8.83MEPS (diluted)
$-13.60Shares Outstanding (diluted)
515.8K+4532026.7%Operating Expenses
$8.93MCash & Debt
$7.28MReturn of Capital
$0.00Revenue by Segment (annual)
$11.21MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $11.51M | $-53.43M | $-803.95 |
| 2024 | $11.69M | $-38.49M | $-4574.07 |
| 2023 | $9.76M | $-41.30M | $-93992.00 |
| 2022 | $11.96M | $-47.45M | $-1899528.00 |
| 2021 | $4.33M | $-52.59M | $-4631759.00 |
| 2020 | $9.38M | $-33.81M | $-11814153.00 |
| 2019 | $5.78M | $-38.54M | $-106403456.00 |
| 2018 | $4.42M | $-32.15M | $-1810550318.00 |
| 2017 | $4.36M | $-21.97M | $-6325593752.00 |
| 2016 | $141.5K | $-14.73M | $-16744218756.00 |
| 2015 | $258.4K | $-16.29M | $-33488437512.00 |
| 2014 | $0.00 | $-8.61M | $-25054312509.00 |
Valuation
JAGXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsaccessnewswire.com·1d ago·Neutral
Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates Company plans to file its Earnings Report on August 19, 2026 on Form 10-Q for the quarter ended June 30, 2026 SAN FRANCISCO, CA / ACCESS Newswire / August 18, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Wednesday, August 19, 2026 at 4:30 p.m. Eastern to review second-quarter 2026 financials and provide corporate updates.
View source ↗
Earnings
Wed, Aug 19(date passed)
Consensus estimate $-52.15 per share
Typical surprise -23.6% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, May 20$-13.60 vs $-71.40beat
- Tue, Apr 7$-3.14 vs $-1.49miss
- Wed, Nov 12$-2.20 vs $-1.78miss
- Thu, Aug 14$-3.59 vs $-2.50miss
- Thu, May 15$-5.84 vs $-3.79miss
- Mon, Mar 31$-5.15 vs $-6.47beat
Estimates and results for JAGX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by JAGX officers and directors.
- Bought
- $830k
- Sold
- —
16 trades
0 trades
- Micek Johnbought
- Micek Johnbought
- King Steven R.bought
- King Steven R.bought
- Siegel Jonathan B.bought
- Siegel Jonathan B.bought
- Conte Lisa Abought
- Conte Lisa Abought
84 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.